Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVELION THERAPEUTICS INC.NVLN · Entity 152369 | Director | August 09, 2018 | August 13, 2018 |
| Nabriva Therapeutics Legacy plcNBRV · Entity 174291 | Director | June 23, 2017 | June 27, 2017 |
| Nabriva Therapeutics plcNBRV · Entity 111497 | Director | August 02, 2022 | August 04, 2022 |
| TREVENA INCTRVN · Entity 85383 | Director | June 13, 2024 | June 14, 2024 |
| Wave Life Sciences, Inc.WVE · Entity 4976 | Director | October 05, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVELION THERAPEUTICS INC.
Report date August 09, 2018 · Filed August 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2028-08-09 | Direct | 50,000 |
Reported balance
After 2018-08-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-08-09 · Grant · Acquired 50,000 · Balance 50,000 F1: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2: The option shall vest in twelve equal monthly installments, beginning one month after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
F2: The option shall vest in twelve equal monthly installments, beginning one month after the grant date.
Nabriva Therapeutics Legacy plc
Report date June 23, 2017 · Filed June 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Expires 2026-08-25 | Direct | 20,200 |
Reported balance
After 2017-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-23 · Other · Acquired 20,200 · Balance 20,200 F1: The exercise price is 6.634 Euro. F2: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F3: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016. |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2026-08-25 | Direct | 10,100 |
Reported balance
After 2017-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-23 · Other · Acquired 10,100 · Balance 10,100 F4: The exercise price is 6.634 Euro. F2: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F5: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is 6.634 Euro.
F2: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
F3: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016.
F4: The exercise price is 6.634 Euro.
F5: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.
Nabriva Therapeutics plc
Report date August 02, 2022 · Filed August 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 7,203 |
Reported balance
After 2022-08-02 transaction · row 1
1 source rowRow 1 · 2022-08-02 · Sale · Disposed 10,297 · Balance 7,203 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1900 to $0.1911, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1900 to $0.1911, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
TREVENA INC
Report date June 13, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2034-06-13 | Direct | 13,700 |
Reported balance
After 2024-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-13 · Grant · Acquired 13,700 · Balance 13,700 F1: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date.
Wave Life Sciences, Inc.
Report date October 05, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,515 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 10,700 · Balance 39,515 F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2036-10-05 | Direct | 64,000 |
Reported balance
After 2026-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-05 · Grant · Acquired 64,000 · Balance 64,000 F2: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
F2: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CoLucid Pharmaceuticals, Inc.
Report date March 01, 2017 · Filed March 01, 2017
Section 16 reporting ended · disclosed 2017-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.79 · Expires 2025-10-27 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-01 · Disposition to issuer · Disposed 8,114 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.24 · Expires 2026-05-10 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-01 · Disposition to issuer · Disposed 8,897 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
F2: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 8, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantStock Option (right to buy) · Derivative | 64,000 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001193125-26-417234 · ownership.xml · derivative · entry 2 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2036-10-05 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. Read SEC document |
| October 05, 2026 Filed Oct 8, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantCommon Stock | 10,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-417234 · ownership.xml · nonDerivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,515 F1 · shares: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 6,515 | $14.07 | $91,633.48 |
DisclosureSEC source: 0001193125-25-314735 · ownership.xml · nonDerivative · entry 2 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,815 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $13.75 to $14.71 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 9,600 | $13.09 | $125,664.00 |
DisclosureSEC source: 0001193125-25-314735 · ownership.xml · nonDerivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,330 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $12.75 to $13.69 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 76,200 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0000950170-25-108291 · ownership.xml · derivative · entry 2 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,200 Underlying: Ordinary Shares · 76,200 shares Expires 2030-08-11 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 12,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-108291 · ownership.xml · nonDerivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,930 F1 · shares: The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 18:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 64,460 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0000950170-24-097286 · ownership.xml · derivative · entry 2 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,460 Underlying: Ordinary Shares · 64,460 shares Expires 2029-08-12 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2024 Non-Employee Director Compensation Policy. The option vests as to 12.5% on a quarterly basis beginning August 12, 2024, through the two-year period following the grant date. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 18:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 32,230 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-097286 · ownership.xml · nonDerivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,230 F1 · shares: The reporting person was granted this restricted share unit award (RSU) pursuant to the 2024 Non-Employee Director Compensation Policy. The RSU vests as to 50% on each of (i) the earlier of the Company's 2025 annual general meeting or August 12, 2025; and (ii) the earlier of the Company's 2026 annual general meeting or August 12, 2026. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:39 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 13,700 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001062993-24-012664 · form4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,700 Underlying: Common Stock · 13,700 shares Expires 2034-06-13 F1 · derivative.exercise_date: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000899243-23-017913 · doc4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires 2028-08-07 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2024 annual general meeting or August 7, 2024. Read SEC document |
| July 18, 2023 Filed Jul 21, 2023 00:51 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 34,250 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001062993-23-015143 · form4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,250 Underlying: Common Stock · 34,250 shares Expires 2033-07-18 F1 · derivative.exercise_date: The options shall vest and become exercisable with respect to one-tweflth (1/12) of the total number of shares subject to the options on a quarterly basis (i.e., every three months) from the Transaction Date listed above, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2023 Equity Incentive Plan, as may be amended from time to time) as of each such vesting date. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000899243-22-029095 · doc4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2027-08-15 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2023 annual general meeting or August 15, 2023. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 18:19 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleOrdinary Shares | 10,297 | $0.19 | $1,956.43 |
DisclosureSEC source: 0001104659-22-086277 · tm2222534-10_4seq1.xml · nonDerivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,203 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1900 to $0.1911, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 18:09 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0000899243-21-033522 · doc4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2026-08-16 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2022 annual general meeting or August 16, 2022. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 20:18 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantShare Options · Derivative | 35,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001104659-21-098423 · tm2123737-3_4seq1.xml · derivative · entry 2 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2031-07-27 F2 · date: The option was granted on July 28, 2021. F3 · derivative.exercise_date: One hundred percent (100%) of the option will vest on July 31, 2022, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 20:18 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantOrdinary Shares | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-098423 · tm2123737-3_4seq1.xml · nonDerivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · balance_after: The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 17:50 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantShare Options · Derivative | 10,500 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001104659-21-077205 · tm2118134-5_4seq1.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2031-06-01 F1 · date: The option was granted on June 2, 2021. F2 · derivative.exercise_date: The option will vest over a three-year period on a monthly pro rata basis beginning on June 2, 2021 and subject to the Reporting Person's continued service on the board of directors of the Issuer. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 18:37 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023093 · doc4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 18:48 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0000899243-19-023038 · doc4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2024-09-04 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 25% of the shares on September 4, 2020 and the remainder vests quarterly thereafter until September 4, 2023. Read SEC document |
| July 31, 2019 Filed Aug 1, 2019 16:20 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantStock Option · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-043346 · a4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2029-07-31 F1 · derivative.exercise_price: The exercise price is $2.38 per share. F2 · derivative.exercise_date: This option was granted on July 31, 2019. One hundred percent (100%) of the option will vest on July 31, 2020, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 16:30 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001104659-18-051500 · a4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2028-08-09 F1 · derivative.exercise_price: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2 · derivative.exercise_date: The option shall vest in twelve equal monthly installments, beginning one month after the grant date. Read SEC document |
| May 02, 2018 Filed May 4, 2018 16:03 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantStock Option · Derivative | 29,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-030626 · a4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Ordinary Shares · 29,000 shares Expires 2028-05-02 F1 · derivative.exercise_price: The exercise price is $4.91 per share. F2 · derivative.exercise_date: This option was granted on May 2, 2018. Vesting began on May 2, 2018 and ends on May 2, 2019. One hundred percent (100%) of the option will vest on May 2, 2019. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 21:31 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantStock Option · Derivative | 10,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-057954 · a4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Underlying: Ordinary Shares · 10,100 shares Expires 2027-09-15 F1 · derivative.exercise_price: The exercise price is $6.86 per share. F2 · derivative.exercise_date: This option was granted on September 15, 2017. Vesting began on September 15, 2017 and ends on September 15, 2018. One hundred percent (100%) of the option will vest on September 15, 2018. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 21:55 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | OtherStock Option · Derivative | 10,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-041903 · a4.xml · derivative · entry 2 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Underlying: Ordinary Shares · 10,100 shares Expires 2026-08-25 F4 · derivative.exercise_price: The exercise price is 6.634 Euro. F2 · kind: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F5 · derivative.exercise_date: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 21:55 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | OtherStock Option · Derivative | 20,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-041903 · a4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,200 Underlying: Ordinary Shares · 20,200 shares Expires 2026-08-25 F1 · derivative.exercise_price: The exercise price is 6.634 Euro. F2 · kind: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F3 · derivative.exercise_date: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016. Read SEC document |
| March 30, 2017 Filed Mar 31, 2017 16:05 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantStock Option (Right to Buy) · Derivative | 9,600 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001104659-17-020692 · a4.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Shares · 9,600 shares Expires 2027-03-30 F1 · derivative.exercise_price: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2 · derivative.exercise_date: The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date. Read SEC document |
| March 30, 2017 Filed Apr 11, 2017 16:02 UTC Amendment | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantStock Option (Right to Buy) · Derivative | 9,600 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001104659-17-022869 · a4a.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Shares · 9,600 shares Expires 2027-03-30 F1 · derivative.exercise_price: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2 · derivative.exercise_price: This Form 4/A is being filed to correct the exercise price reported in the Form 4 filed on March 31, 2017. The correct exercise price is $10.69. F3 · derivative.exercise_date: The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:11 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,897 | $40.26 Strike: $6.24 | $358,193.22 |
DisclosureSEC source: 0000911916-17-000066 · edgar.xml · derivative · entry 2 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,897 shares Expires 2026-05-10 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:11 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,114 | $42.71 Strike: $3.79 | $346,548.94 |
DisclosureSEC source: 0000911916-17-000066 · edgar.xml · derivative · entry 1 CORRIGAN MARK · CIK 0001250661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,114 shares Expires 2025-10-27 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.